Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

640 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chinese guidelines on the management of renal cell carcinoma (2015 edition).
Guo J, Ma J, Sun Y, Qin S, Ye D, Zhou F, He Z, Sheng X, Bi F, Cao D, Chen Y, Huang Y, Liang H, Liang J, Liu J, Liu W, Pan Y, Shu Y, Song X, Wang W, Wang X, Wu X, Xie X, Yao X, Yu S, Zhang Y, Zhou A; written; CSCO Renal Cell Carcinoma Committee. Guo J, et al. Among authors: bi f. Ann Transl Med. 2015 Nov;3(19):279. doi: 10.3978/j.issn.2305-5839.2015.11.21. Ann Transl Med. 2015. PMID: 26697439 Free PMC article. Review. No abstract available.
Expert consensus on maintenance treatment for metastatic colorectal cancer in China.
Xu RH, Shen L, Li J, Xu JM, Bi F, Ba Y, Bai L, Shu YQ, Liu TS, Li YH, Bai CM, Yuan XL, Zhang J, Chen G, Zhou AP, Yuan Y, Wang XJ, Qian XP, Deng YH. Xu RH, et al. Among authors: bi f. Chin J Cancer. 2016 Jan 14;35:13. doi: 10.1186/s40880-015-0067-x. Chin J Cancer. 2016. PMID: 26769299 Free PMC article.
Chinese guidelines on the management of renal cell carcinoma (2015 edition).
Guo J, Ma J, Sun Y, Qin S, Ye D, Zhou F, He Z, Sheng X, Bi F, Cao D, Chen Y, Huang Y, Liang H, Liang J, Liu J, Liu W, Pan Y, Shu Y, Song X, Wang W, Wang X, Wu X, Xie X, Yao X, Yu S, Zhang Y, Zhou A; written on behalf of CSCO Renal Cell Carcinoma Committee. Guo J, et al. Among authors: bi f. Chin Clin Oncol. 2016 Feb;5(1):12. doi: 10.3978/j.issn.2304-3865.2015.11.01. Chin Clin Oncol. 2016. PMID: 26932436 Free article. No abstract available.
CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial.
Shi Y, Li J, Xu J, Sun Y, Wang L, Cheng Y, Liu W, Sun G, Chen Y, Bai L, Zhang Y, He X, Luo Y, Wang Z, Liu Y, Yao Q, Li Y, Qin S, Hu X, Bi F, Zheng R, Ouyang X. Shi Y, et al. Among authors: bi f. Cancer Commun (Lond). 2019 May 24;39(1):28. doi: 10.1186/s40880-019-0374-8. Cancer Commun (Lond). 2019. PMID: 31126331 Free PMC article. Clinical Trial.
Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial.
Xu J, Xu RH, Qin S, Pan H, Bai Y, Chi Y, Wang L, Bi F, Cheng Y, Liu T, Ma D, Shen L, Ba Y, Liang J, Wang X, Yau TCC, Ma BB, Yeh KH, Lin JK, Kappeler C, Shapiro J, Kalmus J, Li J. Xu J, et al. Among authors: bi f. J Gastroenterol Hepatol. 2020 Aug;35(8):1307-1316. doi: 10.1111/jgh.14974. Epub 2020 Jan 28. J Gastroenterol Hepatol. 2020. PMID: 31900959 Free PMC article.
640 results